Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years

PARSIPPANY, N.J., June 5, 2000 -- Aventis Pharmaceuticals announced today that Allegra® (fexofenadine HCl) 30-mg tablets, twice daily (BID), are now available by prescription for the relief of seasonal allergic rhinitis (SAR) and chronic idiopathic urticaria (CIU) in children aged 6 to 11 years.

"Seasonal allergies affect up to six million children in the United States," said Eli Meltzer, M.D., of the Allergy and Asthma Group and Research Center, San Diego, California and lead investigator of the clinical study, Safety of Fexofenadine HCl in Children Treated for Seasonal Allergic Rhinitis. "Allegra 30-mg tablets offer physicians a safe, nonsedating allergy treatment that can help in the management of children's seasonal allergies."

In a study of 411 pediatric patients, Allegra 30-mg tablets BID significantly reduced total symptom scores compared to placebo and was well tolerated among children aged 6 to 11 years. Such allergy symptoms, including runny nose, itchy, watery, red eyes, sneezing and itchy nose, palate and throat can hinder the enjoyment of outdoor activities that children like to pursue.

Allegra 30-mg tablets are nonchewable and are smaller than a chocolate chip. This pediatric dose is an addition to the Allegra family of products currently available for patients 12 and older, including Allegra® (fexofenadine HCl) 60-mg capsules, Allegra-D® (fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg) Extended-Release Tablets and Allegra® (fexofenadine HCl) 180-mg tablets.

Side-Effect Profile
In clinical trials, adverse events with Allegra 30-mg tablets were similar to placebo. The most commonly reported with Allegra 30-mg tablets and placebo in seasonal allergic rhinitis patients 6-11 years are headache (7.2% vs. 6.6%), upper respiratory tract infection (4.3% vs. 1.7%), coughing (3.8% vs. 1.3%), and accidental injury (2.9% vs. 1.3%).

Allegra 60-mg capsules are well tolerated with side effects similar to placebo.

Contact: Charles F. Rouse III
Porter Novelli

Page: 1 2 3

Related medicine news :

1. Aventis Pasteur ready to meet nations needs for tetanus and diphtheria vaccine
2. Aventis Pasteur donates approximately 75 to 90 million doses of smallpox vaccine to the U.S.
3. Aventis Pasteur statement on HVTN 501 decision
4. Millennium, Aventis Pharma form novel alliance
5. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
6. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
7. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
8. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
9. Pharmaceuticals and personal care products
10. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
11. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis

Post Your Comments:

(Date:8/14/2018)... ... August 14, 2018 , ... Eagle Merchant Partners and ... provider of residential and commercial recreational surfacing products across the country. , The ... used across a wide range of markets and customers. Founded in 1998, Recreational ...
(Date:8/11/2018)... ... August 10, 2018 , ... Dr. Siavash Eftekhari, Oral and Maxillofacial Surgeon ... a week-long international outpost trip to deliver dental care in impoverished communities. Along with ... Dr. Eftekhari volunteered his time to help deliver care to over 550 individuals in ...
(Date:8/11/2018)... ST. PETERSBURG, Fla. (PRWEB) , ... August 10, 2018 , ... ... health and wellness of children in the region by utilizing a population health perspective ... of a population by ensuring families are being treated at the right facility or ...
(Date:8/11/2018)... ... August 11, 2018 , ... Financial ... Award in the Executive of the Year-Business category in The 15th Annual International ... program. All individuals and organizations worldwide – public and private, for-profit and non-profit, ...
(Date:8/9/2018)... ... 2018 , ... Lyme disease is one of the fastest growing epidemics to ... – a 25-fold increase since surveillance began in 1982. According to a new report ... states and the District of Columbia. Yet, Lyme and other insect borne illnesses are ...
Breaking Medicine News(10 mins):
(Date:8/2/2018)... ... August 02, 2018 , ... ... gummy smile for custom crown lengthening treatment at his Eden Prairie, ... line and an unsteady self-conscious. Using decades of experience, Dr. Sanchez is excited ...
(Date:8/2/2018)... ... August 02, 2018 , ... Juan M. Montero, ... international leader of sustainable advocacy. Sharon Kleyne, host of the internationally syndicated radio ... & Your Health sponsored by Nature’s Tears® EyeMist® on VoiceAmerica and World Talk ...
(Date:8/2/2018)... ... August 02, 2018 , ... The Team from Hennessey Performance (HPE) has built ... production of a limited production commemorative vehicle: The 2019 Hennessey Heritage Edition Mustang. ... V8 engine produces 808 horsepower at 7,200 rpm and 677 lb-ft of torque at ...
Breaking Medicine Technology:
Cached News: